285 related articles for article (PubMed ID: 2553253)
1. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin.
Bjornsti MA; Benedetti P; Viglianti GA; Wang JC
Cancer Res; 1989 Nov; 49(22):6318-23. PubMed ID: 2553253
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.
Madden KR; Champoux JJ
Cancer Res; 1992 Feb; 52(3):525-32. PubMed ID: 1310066
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
4. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
Eng WK; Faucette L; Johnson RK; Sternglanz R
Mol Pharmacol; 1988 Dec; 34(6):755-60. PubMed ID: 2849043
[TBL] [Abstract][Full Text] [Related]
5. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast.
Wasserman RA; Austin CA; Fisher LM; Wang JC
Cancer Res; 1993 Aug; 53(15):3591-6. PubMed ID: 8393377
[TBL] [Abstract][Full Text] [Related]
6. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
7. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
Alessandri M; Beretta GL; Ferretti E; Mancia A; Khobta A; Capranico G
J Mol Biol; 2004 Mar; 337(2):295-305. PubMed ID: 15003448
[TBL] [Abstract][Full Text] [Related]
8. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
9. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide.
Hwang JL; Shyy SH; Chen AY; Juan CC; Whang-Peng J
Cancer Res; 1989 Feb; 49(4):958-62. PubMed ID: 2536295
[TBL] [Abstract][Full Text] [Related]
10. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.
Lotito L; Russo A; Bueno S; Chillemi G; Fogli MV; Capranico G
Eur J Pharmacol; 2009 Jan; 603(1-3):29-36. PubMed ID: 19094980
[TBL] [Abstract][Full Text] [Related]
11. Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1.
Liu C; Pouliot JJ; Nash HA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14970-5. PubMed ID: 12397185
[TBL] [Abstract][Full Text] [Related]
12. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage.
Holden JA; Wall ME; Wani MC; Manikumar G
Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978
[TBL] [Abstract][Full Text] [Related]
13. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
14. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
[TBL] [Abstract][Full Text] [Related]
15. [Effect of camptothecin on the DNA-relaxing and DNA-cleavage activity of calf thymus topoisomerase I].
Bronshteĭn IB; Gromova II; Bukhman VL; Kafiani KA
Mol Biol (Mosk); 1989; 23(2):491-501. PubMed ID: 2549395
[TBL] [Abstract][Full Text] [Related]
16. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex.
Wang X; Zhou X; Hecht SM
Biochemistry; 1999 Apr; 38(14):4374-81. PubMed ID: 10194356
[TBL] [Abstract][Full Text] [Related]
17. Luotonin A. A naturally occurring human DNA topoisomerase I poison.
Cagir A; Jones SH; Gao R; Eisenhauer BM; Hecht SM
J Am Chem Soc; 2003 Nov; 125(45):13628-9. PubMed ID: 14599178
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
19. Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin.
Bjornsti MA; Knab AM; Benedetti P
Cancer Chemother Pharmacol; 1994; 34 Suppl():S1-5. PubMed ID: 8070016
[TBL] [Abstract][Full Text] [Related]
20. Expression, purification and DNA-cleavage activity of recombinant 68-kDa human topoisomerase I-target for antitumor drugs.
Bronstein IB; Wynne-Jones A; Sukhanova A; Fleury F; Ianoul A; Holden JA; Alix AJ; Dodson GG; Jardillier JC; Nabiev I; Wilkinson AJ
Anticancer Res; 1999; 19(1A):317-27. PubMed ID: 10226561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
